Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide

Diabetes Research and Clinical Practice
Renate E van GenugtenMichaela Diamant

Abstract

Type 2 diabetes (T2DM) is a heterogeneous syndrome, characterized by beta-cell failure in the setting of obesity-related insulin resistance. T2DM has a progressive course and is associated with a high cardiovascular disease (CVD) risk, regardless of the treatment used. The incretin hormones glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP) are secreted in the gut upon meal ingestion and lower blood glucose by glucose-dependent stimulation of insulin secretion and production. Exogenously administered GLP-1 lowers postprandial glucose excursions by inhibiting glucagon secretion and delaying gastric emptying, improves beta-cell function, and promotes satiety and weight loss. Native GLP-1 is degraded rapidly by the ubiquitous enzyme dipeptidyl-peptidase (DPP)-4. Thus, injectable DPP-4-resistant GLP-1 receptor agonists (GLP-1RA) and oral DPP-4 inhibitors have been developed. Exenatide is the first GLP-1RA that became available for the treatment of T2DM patients. Exenatide has unique characteristics, as to date it is the only agent that addresses the multiple defects of the T2DM phenotype, including hyperglycaemia, islet-cell dysfunction, alimentary obesity, insulin resistance, hypertension and dysl...Continue Reading

References

Jan 1, 1986·Diabetologia·M NauckW Creutzfeldt
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Dec 24, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xiaokun DingFrank A Anania
Mar 7, 2006·Cell Metabolism·Daniel J Drucker
Sep 7, 2006·Liver International : Official Journal of the International Association for the Study of the Liver·Maarten E TushuizenRobert J Heine
Dec 13, 2006·BMJ : British Medical Journal·R J HeineD M Nathan
Feb 20, 2007·Pharmacology & Therapeutics·Máire E Doyle, Josephine M Egan
May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker
Oct 12, 2007·Physiological Reviews·Jens Juul Holst
Mar 13, 2008·American Journal of Physiology. Endocrinology and Metabolism·Antonio CerveraEugenio Cersosimo
May 3, 2008·The New England Journal of Medicine·Pablo CureRodolfo Alejandro
Aug 30, 2008·Endocrine Reviews·Norbert StefanHans-Ulrich Häring
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanDavid R Matthews

❮ Previous
Next ❯

Citations

Aug 3, 2010·Acta Pharmacologica Sinica·Ming-wei WangCai-hong Zhou
Jan 10, 2012·Diabetes, Obesity & Metabolism·N J van der ZijlM Diamant
Jun 2, 2012·World Journal of Gastroenterology : WJG·Meir MizrahiYaron Ilan
Nov 13, 2015·Drug Development and Industrial Pharmacy·Yu ZhangZhirong Zhang
Sep 21, 2013·Expert Opinion on Drug Discovery·Maliheh SafaviMohammad Abdollahi
Dec 3, 2013·International Journal of Cardiology·F J P BerninkY Appelman
Oct 23, 2012·International Journal of Cardiology·Flip J P BerninkYolande Appelman
Apr 21, 2012·Diabetes Care·Michaela Diamant, Michiel van Agtmael
Dec 11, 2013·The Journal of Endocrinology·L van BloemendaalM Diamant
Oct 6, 2010·Diabetes, Obesity & Metabolism·R A CantrellJ Sierra-Johnson
Oct 22, 2013·Natural Product Reports·Armin Bauer, Mark Brönstrup
Nov 10, 2010·Expert Opinion on Therapeutic Targets·Victoria K Gatenby, Mark T Kearney

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.